Trademark Search in Canada

DESIGN

View On IC.GC.CA

REGISTERED

on 30 Nov 2021

TM5 Status

LIVE/REGISTRATION/Issued and Active

Your registration has been issued and is active. You can now use the TM5 mark.

Last Applicant/ Owned by

ALNYLAM PHARMACEUTICALS INC. A LEGAL ENTITY

300 Third Street Cambridge, MA 02142

Serial Number

1911137 filed on 24^th Jul 2018

Registration Number

TMA1114973 registered on 30^th Nov 2021

Registration expiry Date

30^th Nov 2031

Correspondent Address

RICHES, MCKENZIE & HERBERT LLP

SUITE 18002 BLOOR STREET EASTTORONTO

ONTARIO

M4W3J5

DESIGN

Trademark usage description

pharmaceutical preparations, namely, rna therapeutics for use in the treatment of cancer, hiv, hepatitis a, hepatitis b, influenza, measles, neurodege Read More

Vienna Information

2 . 1 . 30

Other menAutres hommes

2 . 1 . 23

Men stylizedHommes stylisés

26 . 11 . 2

Two lines or bandsDeux lignes ou bandes

26 . 11 . 12

Curved lines or bands (except a 26.11.13)Lignes ou bandes courbes (excepté a 26.11.13)

26 . 1 . 1

CirclesCercles

26 . 1 . 3

One circle or ellipseUn cercle ou une ellipse

26 . 1 . 24

Circles or ellipses with dark surfaces or parts of surfacesCercles ou ellipses avec surface ou partie de la surface foncée

27 . 5 . 1

Letters presenting a special form of writingLettres présentant un graphisme spécial

27 . 5 . 21

One letterUne lettre

Classification Information

Class [005]
Pharmaceutical preparations, namely, RNA therapeutics for use in the treatment of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection; Pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes for use in the treatment of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection; pharmaceutical preparations, namely, RNA therapeutics

Classification kind code

Mark Details

Serial Number

1911137

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 190 on 29^th Sept 2021	Registration Pending
Submitted for opposition 191 on 29^th Sept 2021	Registration Fee Notice Sent
Submitted for opposition 42 on 7^th Jul 2021	Advertised
Submitted for opposition 26 on 14^th Jun 2021	Approved
Submitted for opposition 27 on 14^th Jun 2021	Approval Notice Sent
Submitted for opposition 22 on 2^th Oct 2020	Search Recorded
Submitted for opposition 20 on 2^th Oct 2020	Examiner's First Report
Submitted for opposition 31 on 31^st Jul 2018	Formalized
Submitted for opposition 30 on 24^th Jul 2018	Filed
Submitted for opposition 1 on 24^th Jul 2018	Created